Schizophrenia is a debilitating, costly, socially disruptive, life-threatening disease in which available treatments are largely palliative and empirical, and produce significant short-and long-term side effects. Therefore, a strong case can made for exploring alternative treatments with a rational basis for use in this disease. Considerable evidence indicates that autoimmune processes may be involved in some forms of schizophrenia, including altered risk of certain autoimmune diseases in patients and their relatives, shared epidemiological features, and apparent involvement of genes known to influence the immune response repertoire. Attempts to provide direct evidence for autoimmune processes have proven elusive, possibly due to the technical difficulty inherent in accessing autoantibodies with high affinity for brain cell-surface receptors. In view of this impasse, we argue for a well-designed trial in schizophrenia of immunosuppressive therapy, which is now the mainstay of therapy for many autoimmune diseases. Analysis of disease states in which immunosuppression has been effectively used over many decades provides guidelines necessary for a meaningful trial.
Autoimmune processes in schizophrenia?
Evidence pointing to autoimmune processes in schizophrenia includes:
Altered risk of certain autoimmune diseases in patients with schizophrenia, or their close relatives. A recent study based on the Danish Psychiatric Register found that 'a history of any autoimmune disease was associated with a 45% increase in risk for schizophrenia. ' 1,2 'Nine autoimmune disorders had higher prevalence rates among patients with schizophrenia than among comparison subjects y and 12 autoimmune diseases had higher prevalence rates among parents of schizophrenia patients than among parents of comparison subjects.' Wright et al. 3 found schizophrenic patients with an affected first-degree relative were significantly more likely to have a parent or sibling with an autoimmune disease. A significant excess of insulin-dependent diabetes mellitus (IDDM) was found in the parents and siblings of patients with schizophrenia. 3 These findings are consistent with shared genetic predisposition for these various diseases, and suggest a commonality of mechanism.
Earlier reports indicated a strong dissociation between schizophrenia and rheumatoid arthritis, 4 and between schizophrenia and IDDM. 5 Three possible explanations for these dissociations are:
(a) drugs used in treating one disease may protect from, or inhibit, the other; (b) metabolic alteration associated with one disease may inhibit the other; (c) genes predisposing to one disease may protect against the other. For example, the histocompatibility gene HLA-DR2 confers a 130-fold increased risk of narcolepsy (possibly autoimmune), a 2.7-fold increased risk of multiple sclerosis (probably autoimmune), and a 13-fold increased risk of Goodpasture's disease (autoimmune). The same gene confers a 10-fold decreased risk of IDDM, and a 25-fold decreased risk in Japanese of pemphigus vulgaris, 6 both autoimmune diseases.
Schizophrenia shares several features with known or suspected autoimmune diseases 7, 8 such as Graves' disease, IDDM, pernicious anaemia, rheumatoid arthritis and multiple sclerosis, including:
(a) tendency to run in families; (b) approximately 50% discordance in monozygotic twins; (c) predisposition caused by a combination of genes rather than by a single gene; (d) 'juvenile grace gap' and random age of onset; (e) remitting and relapsing course; (f) involvement of infectious triggers and other environmental precipitants including (in schizo-phrenia) prenatal infection, 9,10 influenza infection, 11 head injury 12 and drug abuse. 13 
Reported immunological abnormalities in schizophrenia include
(a) oligoclonal antibodies in cerebrospinal fluid (CSF), suggesting antibody synthesis within the central nervous system (CNS). 14 This is reminiscent of findings in multiple sclerosis of 'a B-cell response to a specific antigen occurring in the central nervous system, whereas corresponding clones are absent from the peripheral circulation'; 15 (b) elevated soluble interleukin-2 (IL-2) receptors in serum, comparable to elevations in rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis -all known or suspected to be autoimmune. Increased levels of IL-2 in CSF, 16 correlating with recurrence of symptoms in schizophrenia; 17 (c) increased interleukin-6 (IL-6) 18 indicative of immune system activation; (d) increased numbers of CD5 þ B lymphocytes, 19 similar to autoimmune diseases including rheumatoid arthritis, progressive systemic sclerosis, Graves' disease, Sjogren's syndrome and IDDM. 20 Many genetic studies in schizophrenia have implicated genes known to determine predisposition to autoimmune diseases especially genes associated with the major histocompatibility complex (MHC). 21 To some extent this could be due to the fact that these are highly polymorphic loci that researchers have found it convenient to study. There is some consensus that HLA A9 (or its A24 subspecificity) may confer an increased risk of schizophrenia. 21 Wright et al.
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concluded that 'there is some evidence that DQB1*0602 and/or DRB1*04 alleles (or alleles at linked loci) may protect against schizophrenia.' They rightly point out that 'taken together, however, HLA association investigations provide only weak evidence for the existence of either resistance or susceptibility loci for schizophrenia close to the HLA region at the 6p21.3 band.'
A seven fold relative risk of schizophrenia has been reported in subjects with the complement C4BQO allele; 22 this finding is particularly interesting because C4A and C4B null alleles have been reported to be associated with several autoimmune diseases including systemic lupus erythematosus (SLE), IDDM, subacute sclerosing panencephalitis and autoimmune chronic active hepatitis. 23 These C4 null associations may be due to linkage with other MHC genes, the C4 deficiency itself, or both. Indications are that, in diseases such as IDDM and multiple sclerosis, susceptibility is determined by a combination of: HLA Class II (D locus), MHC Class III (complement) genes, antibody structural genes and T lymphocyte receptor genes. [24] [25] [26] [27] [28] [29] These are all genes expected to influence the immune response repertoire. According to Riley 32 ), 8p22-p21, 6p24-p22, 13q14-q32, 6q21-q22 and 1q21-22. 32 The candidate genes that researchers have focussed on are those having some obvious connection with brain pathways and mechanisms. However, of particular interest to the thesis advanced here is that several of these linkage regions are closely associated with loci related to the immune system. For example, the 6p24-p22 is adjacent to the MHC (6p21), the 'most important region in the vertebrate genome with respect to infection and autoimmunity'; 33 the 1q21-22 region includes two immunoglobulin Fc receptor loci, both at 1q21; the 22q11-13 region includes the IGL (immunoglobulin lambda) genes (at 22q11.2), including the lambda light chain variable region genes, which provide a key component of the immune response repertoire. These immune system-related genes may have been overlooked as candidates by researchers focussing on genes obviously connected with neural, rather than immune, processes. The tentative hints that have so far come from genetic studies in schizophrenia appear compatible with multiple genes influencing immune response repertoire involvement in this disease, as in many known autoimmune diseases. 34 The uniquely effective 'atypical' antipsychotic clozapine 1 is more potent than would be predicted from its pharmacological profile as a dopamine D2 receptor antagonist. This has led to speculation that its mode of action involves serotonin or other receptor systems. A well recognized and problematic adverse effect of clozapine is granulocytopenia and, more rarely, agranulocytosis, leading to the standard practice of monitoring white blood cell counts during treatment. However, it is clear that clozapine has effects on hematopoietic cells other than granulocytes, leading to the possibility that one of its effects, or even its main effect, may be to diminish antibody synthesis. Indeed McAllister et al. 35 note that 'several patients treated with clozapine had a significant reduction in B lymphocytes (i.e. antibody-secreting cells) despite an insignificant change in the total white blood cell count.' However, these authors were seeking an increase in B-cell numbers in support of the hypothesis that the agranulocytosis was autoantibody-mediated so the observation received no further comment. Others have observed that clozapine increases soluble IL-2 receptor levels, and concluded that this may be one mechanism by which clozapine causes immunosuppression. 36 The extent to which antipsychotic drugs other than clozapine share its immune effects is uncertain, although Leykin et al. 37 found that haloperidol also can be immunosuppressive.
Anti-brain antibodies. Although it is tempting to cite reports of anti-brain autoantibodies as supporting evidence for an autoimmune basis for schizophrenia, these have proven controversial and lacking in reproducibility. 38 Antibodies with high affinity for specific brain antigens, such as cell-surface receptors, 8 would likely become bound soon after synthesis and therefore unlikely to occur in measurable concentrations in CSF -let alone in blood. This highlights the difficulty of providing convincing direct evidence for or against an autoimmune hypothesis.
Immunosuppressive drug therapy
In view of the above accumulated data indicating possible autoimmune mechanisms in schizophrenia, an adequate trial of immunosuppressive therapy is called for -namely synthetic corticosteroids, perhaps coupled with azathioprine or 6-mercaptopurine (both thiopurines). The reason for past reluctance to use corticosteroids may stem from a belief expressed in the psychiatric literature and in pharmacology textbooks that a history of mental illness contraindicates their use. This does not appear well-founded, and is based mainly on anecdotal case reports rather than on controlled studies. In contrast, the Boston Collaborative Drug Surveillance Program 39 analysed the hospital records of 718 patients treated with prednisone for various diseases. Twenty-one patients (3%) experienced acute psychiatric symptoms; eight exhibited inappropriate euphoria while 13 became psychotic with manifestations including hallucinations, delusions, violent behaviour, mania or severe depression. The euphoric patients recovered following reduction in dosage, whereas the psychotic patients required additional brief antipsychotic therapy. This study found a statistically significant dose-response effect, with psychiatric symptoms recorded in: 1.3% (6/463) patients receiving 40 mg/day or less; 4.6% (8/175) of those receiving 41-80 mg/day; and in 18.4% (7/38) of those receiving 80 mg/day or more. 39 Pre-existing psychiatric illness was not found to increase the likelihood of an adverse reaction to corticosteroids beyond that in the general population, 39, 40 despite the contrary view in some earlier textbooks.
Trials of cortisone in schizophrenia
In the 1950s natural steroids, in particular cortisone, were found ineffective in ameliorating the symptoms of schizophrenia, despite an earlier optimistic report. 41 It may be unfortunate that the water became muddied by early attempts when the only compounds available were of low therapeutic index, thereby necessitating the use of large doses causing major adverse effects. The first of these studies set out to test whether adrenal insufficiency contributed to schizophrenia. 41 Twenty-one patients with chronic schizophrenia who had been ill for more than 6 years were given intensive cortisone therapy, and six of the 21 were reportedly cured and discharged from hospital; paranoid patients were the most responsive to treatment. 41 Unfortunately, these spectacular results could not be confirmed in subsequent studies; 42, 43 the reason for this discrepancy is not clear. It could be significant that the study which reported a beneficial effect used a relatively low dose (typically 100 mg cortisone daily) for one to two weeks, followed by an even lower dose (50 mg daily) for a sustained period of 6-8 weeks or more. 41 In contrast, the subsequent studies 42, 43 used 400-500 mg/day of cortisone, which would be regarded as massive today. As a result of the severity of the side effects of these huge doses, treatment lasted only 3 weeks in one study, and 3-10 weeks in another. In this latter study, 43 three patients showed slight and transient psychiatric improvement whereas five were made worse. Interestingly, one female patient showed definite improvement, but when the dose was dropped to below 100 mg per day showed exacerbation of symptoms. When the dose was increased to 200 mg per day the psychotic manifestations abated, but reappeared when the dose was lowered again. 43 As detailed below, cortisone tends to be ineffective in treating exophthalmos associated with Graves' disease, in contrast to the synthetic corticosteroids prednisone and prednisolone, which have a higher therapeutic index and are strikingly effective in treating this and other autoimmune diseases. 44 
Other immune-related therapies tried in schizophrenia
Efforts to test the efficacy of plasma exchange in schizophrenia proved negative, and this was interpreted as counting against an autoimmune hypothesis. 45 However, it is doubtful whether such a procedure would succeed in removing autoantibodies from the brain side of the blood-brain barrier, particularly if autoantibody synthesis were localized in the brain. Recent proposals -together with preliminary supporting data -have advocated use of adoptive immunotherapy with in vitro-activated immune cells in schizophrenia and other mental disorders. 46, 47 The proposed mechanism of action is 'some kind of restoration of distorted cytokine levels important for neuronal function'. 47 We feel that it is premature to comment on this proposed therapeutic strategy until further work supports or refutes it. Nonsteroidal anti-inflammatory drugs have been investigated for their potential to attenuate or prevent cognitive impairment in schizophrenia. A prospective double-blind study of supplementary treatment with celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reported a beneficial effect during the acute phase compared with risperidone therapy alone. 48 However, a subsequent international multi-centre trial could not demonstrate any benefit of celecoxib treatment. 49 Riedel et al. 49 argue 'duration of illness may have been the reason for an apparent nonresponse to celecoxib treatment.' The hypothesized therapeutic effect of celecoxib on the psychopathology of schizophrenic patients was thought to be based on inhibition of COX activity. 48 However, COX-2 expression has been found to not be upregulated in the hippocampus of schizophrenia cases, in contrast to what is observed in Alzheimer's disease. 50 The equivocal nature of findings using these diverse alternative immune-related therapies in our view strengthens the case for using mainstream immunosuppressive therapy which is tried and true in a whole range of medical disorders, as discussed below.
Mode of action of immunosuppressive drugs
There are several major categories of immunosuppressive agents, including X-irradiation (used mainly for its cytocidal effects on certain types of neoplastic cells), anti-lymphocyte globulin, cytotoxic agents, corticosteroids, calcineurin inhibitors such as cyclosporine and related agents, more targeted inhibitors of purine and pyrimidine metabolism such as mycophenolate mofetil and leflunomide and newer 'biological' agents aimed at more specific cells, receptors and cytokines involved in immune interactions. 40 The semi-selective action of many of these agents is based on the rapid cell division that distinguishes cells of the immune system from other tissues, particularly when participating in a current immune response. It follows that cells which are part of an active immune response at the time of treatment will be more affected than cells which represent either immunological 'memory', or that part of the immune response repertoire which is potential rather than realized.
Commonly used cytotoxic drugs include cyclophosphamide (an alkylating agent), azathioprine (a purine analogue antimetabolite), and methotrexate (a folic acid antagonist). These agents have been used mainly in diseases in which corticosteroid therapy was found to be partially effective. Combining cytotoxic agents with steroids results in greater efficacy, especially in more severe disease such as lupus nephritis. Combined use of steroids and cytotoxic agents also incorporates a 'steroid sparing' strategy based on the concept that administering two drugs with distinct modes of action often enables use of lower doses, thus minimizing side effects associated with high doses of corticosteroids. Alkylating agents such as cyclophosphamide have severe side effects including infection, ovarian failure and carcinogenesis, which restricts use to life threatening disease. Thus, the current trend in treatment of lupus nephritis, for example, is to use a short induction course of cyclophosphamide followed by maintenance with a safer treatment such as azathioprine or mycophenolate mofetil. 40, 51 The adrenal cortex synthesizes two classes of steroids from cholesterol (the corticosteroids with 21 carbon atoms and the adrenal androgens with 19 carbons) by a series of enzymatic conversion steps.
Corticosteroids are not stored in the adrenal, but are synthesized at the rate required for normal secretion. Corticosteroids control protein synthesis by binding to receptors in sensitive cells and regulating the transcription of mRNA. Corticosteroids profoundly alter the immune responses of lymphocytes and are of immense value in treating diseases that result from undesirable immune reactions. 40 Sub-populations of lymphocytes are differentially affected, and the clinical effects of steroid therapy are often greater than can be explained simply in terms of lymphocyte numbers. In part, their action concerns alterations in distribution between different lymphocyte pools. Multiple other mechanisms are involved in the suppression of immune inflammation by glucocorticoids, including inhibition of the production of pro-inflammatory cytokines such as IL-1 and TNF, and the production of critical enzymes such as COX-2 and iNOS. 52 Side effects from corticosteroids are correspondingly profound, necessitating use of the smallest dose possible and attention to amelioration of predictable consequences. According to Goodman & Gilman's Pharmacological Basis of Therapeutics:
40 'Because they exert effects on almost every organ system, the clinical use of and withdrawal from corticosteroids are complicated by a number of serious side effects, some of which are life threatening. Therefore, the decision to institute therapy with corticosteroids always requires careful consideration of the relative risks and benefits in each patient.' Among the potential side effects from prolonged therapy are: cataracts, fluid and electrolyte imbalances, fat redistribution, hypertension, hyperglycaemia, increased susceptibility to infection, myopathy, osteoporosis, osteonecrosis, and psychosis. Despite these dose-related side effects, the usefulness of corticosteroids in effectively treating a wide variety of inflammatory and autoimmune diseases makes them among the most frequently prescribed classes of drugs. 40 Potential interactions with other drugs [53] [54] [55] are shown in Table 1 . These require careful consideration, but none of the known interactions would preclude combining corticosteroids and/or azathioprine with anti-psychotic medication, with the possible exception of clozapine.
Immunosuppressive therapy of selected autoimmune diseases
Corticosteroids and other immunosuppressive drugs have been widely used in treating autoimmune conditions, including those mediated by autoantibodies, for example myasthenia gravis, Graves' disease, thrombocytopenia, warm type haemolytic anaemia, pemphigus vulgaris.
Myasthenia gravis
There is some controversy about the best form of therapy to use in treating myasthenia gravis -a disease caused by autoantibodies against the acetylcholine receptor on muscle cells. 56 Thymectomy, corticosteroids, and other forms of immunosuppression are all useful in treatment. 57 In a study of 116 myasthenic patients treated with corticosteroids, 58 a satisfactory outcome (marked improvement or remission) was reported in 80.2%. The outcome was unsatisfactory in the remaining 19.8%, with 5.2% being unimproved and 14.7% showing only moderate improvement. The dose used was 60-80 mg daily until improvement was noted on each of 3 successive days, then an equivalent alternate-day regime was instituted. It is noteworthy that 56 patients (48%) showed an initial exacerbation, which in 8.6% was severe; occurrence of exacerbation was not related to degree of ultimate improvement. 58 This could be relevant to the finding in the cortisone trials in schizophrenia of exacerbation in some patients, resulting in early termination of the treatment. 42, 43 Of the 93 myasthenic patients who responded satisfactorily, the duration of therapy to the time of maximal improvement ranged from 2 weeks to 6 years, with the median time to maximal improvement being 5.5 months. The period required to achieve a state of marked improvement ranged from 1.5 weeks to 18 months, mean 3.1 months. 58 Of relevance to the present proposal is that the frequency of 'psychological disturbance' was 3 of 129 patients or 2.3%, closely matching the figure reported in the Boston Collaborative Study. 39 Exophthalmos, pretibial myxoedema and hyperthyroidism of Graves' disease The complications of Graves' disease are presumed to be caused by variants of thyroid-stimulating autoantibodies that have a high affinity for receptors on tissue in the orbit and the shins, respectively. The core pathology of Graves' disease is hyperthyroidism, caused by thyroid-stimulating autoantibodies. This can be effectively controlled by surgical sub-total thyroidectomy, partial ablation of the thyroid with radioiodine, or by use of anti-thyroid drugs, so there has been no reason to investigate immune suppression as a means of controlling this disease. However, recently, a patient with extreme thyrotoxicosis was found to be resistant to the anti-thyroid drugs carbimazole and propylthiouracil, causing him to be treated effectively with prednisone, 40 mg daily. 44 Cortisone was used for treating exophthalmos in the 1950s, there being controversy regarding its effectiveness. 59 However, substitution of prednisone, 'resulted in effective and remarkable degrees of control', leading to retention of vision in patients who would otherwise have lost it. 59 Pretibial myxoedema is cured by topical application of corticosteroids. 40 Hemolytic anaemia Corticosteroids and azathioprine are regarded as the treatment of choice for warm-type autoimmune haemolytic anaemia. 40 Cyclophosphamide is also used, but the multi-system toxicity and oncogenic potential of this and other alkylating agents indicate that they should only be used when corticosteroids and azathioprine fail. Approximately 50% of patients who do not respond to corticosteroid treatment will respond to combined therapy of azathioprine plus low-dose corticosteroids.
40 Table 1 Known drug interactions between corticosteroids, azathioprine, anti-psychotic drugs used in treating schizophrenia, and other drugs which patients could be taking for unrelated reasons [53] [54] [55] A Drugs reported to possibly decrease therapeutic effects of corticosteroids: 54, 55 Antacids; barbiturates; carbamazepine; ephedrine; hydantoins (e.g. phenytoin); rifamycins (e.g. rifabutin, rifampicinalso known as rifampin, rifapentine). B Drugs reported to possibly potentiate therapeutic and toxic effects of corticosteroids: 54, 55 Aprepitant; azole antifungal agents (e.g. fluconazole, itraconazole, ketoconazole, miconazole, voriconazole); diltiazem; estrogens; grapefruit juice; macrolide antibiotics (e.g. clarithromycin, erythromycin, troleandomycin); nefazodone. C Drugs reported to have adverse interactions with corticosteroids: 54 Potassium-depleting diuretics (severe depletion may occur if used together); beta blockers (an isolated report of hyperkalemia). (Also, epilepsy may be exacerbated by use of corticosteroids; great care needed in glaucoma, peptic ulceration, and acute infections.) D Reported interactions between antipsychotics and corticosteroids: 53 Dexamethasone (steroid) is listed as a medicine-type that has a low degree of inhibition of antipsychotics of the type that are metabolized by the cytochrome P450 CYP3A subsystem (i.e. chlorpromazine, clozapine, haloperidol, mesoridazine, pimozide, quetiapine, sertindole, ziprasidone). E Drugs reported to potentiate therapeutic effects and toxicity of azathioprine: 54 Allopurinol; balsalazide; mesalazine; olsalazine; sulfasalazine; Hematological toxicity (potentially life-threatening) by co-trimoxazole or trimethoprin; hepatotoxicity increased by doxorubicin. F Drugs contraindicated in patients treated with clozapine: 54 Because clozapine can cause blood dyscrasias and potentially fatal agranulocytosis, it should not be given with other drugs that can cause agranulocytosis including: Cytotoxic drugs (e.g. azathioprine); carbamazepine; co-trimoxazole; chloramphenicol; penicillamine; phenylbutazone; pyrazolone analgesics; sulphonamides.
Goodpasture's syndrome Standard treatment consists of plasma exchange, to remove the anti-basement membrane antibodies, coupled with immunosuppressive therapy. 40 
Pemphigus vulgaris
Patients with pemphigus vulgaris produce IgG antibodies directed against squamous epithelial cell surfaces. 40, 57 This once-fatal disease is now regarded as controllable with corticosteroids, or combined therapy with corticosteroids plus cytotoxic drugs such as azathioprine, methotrexate or cyclophosphamide. 40 
Use of immunosuppressive agents in treating brain diseases
Autoimmune diseases affecting the brain require special consideration. The 'sanctuary effect' created by the blood-brain barrier prevents many drugs from achieving cytotoxic concentrations within the CNS. 60 Corticosteroids have been used to treat brain tumours and acute lymphoblastic leukaemia involving the meninges, and differences have been noted in the efficacy of dexamethasone and prednisone for these uses. 60, 61 After intravenous bolus injection into rhesus monkeys, dexamethasone and prednisolone were found to reach equally potent peak concentrations in the CSF. However, prednisolone had a shorter halflife in the CSF than did dexamethasone, attributable to its greater tendency to bind to plasma proteins. It was estimated that CSF levels of prednisolone following standard oral doses would be 5-to 10-fold lower than those achieved with an equipotent systemic dose of dexamethasone. 61 Patients with acute lymphoblastic leukaemia had a significantly lower rate of CNS relapse when treated with dexamethasone than with prednisone. 62 Systemic lupus erythematosus Systemic lupus erythematosus (SLE) is an autoimmune disease in which CNS involvement is observed in approximately 14% of cases. 63 The standard approach to treatment of severe cases involves the use of high dose prednisone and cyclophosphamide and other strategies using prednisone and azathioprine administered systemically, similar to treatment of lupus renal disease. 64 It is thought that abnormalities of the blood-brain barrier exist in SLE, allowing access of systemic treatments to the CNS. 65 However, one innovative approach reported the use of combination therapy with methotrexate and dexamethasone intrathecally. 63 Multiple sclerosis Various immunosuppressive therapies have been tried in multiple sclerosis, 40 including: corticosteroids and cyclophosphamide, azathioprine, cyclosporin A, interferon-beta, and anti-lymphocyte globulin. 15 A recent addition is natalizumab, a recombinant monoclonal antibody, which is the first selective immunomodulating drug for the treatment of multiple sclerosis. 66 Treatment options are most effective during the relapsing-remitting phase, and largely ineffective during the later progressive neurodegenerative phase. 15 Relevant considerations for an effective trial of immunosuppression in schizophrenia (1) Dexamethasone is more likely than prednisone or prednisolone to achieve potentially therapeutic concentrations within the brain because of its lower tendency to bind to plasma proteins. (2) A combination of dexamethasone plus azathioprine is likely to be better tolerated than either drug alone, because the dose of each can be kept lower. This combination of corticosteroid plus cytotoxic drug is a thoroughly tried and tested form of therapy in autoimmune diseases. Azathioprine also has the advantage that measurement of thiopurine methyl transferase (TPMT) before treatment may limit the occurrence of neutropenia, and levels of 6-thioguanine nucleotide, the principal therapeutic metabolite, can be measured.
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(3) A realistic aim is not to 'cure', but to reduce psychotic and other symptoms, and thereby help to preserve or restore function. Clearly immunosuppressive therapy cannot terminate an autoimmune process without turning off the entire immune system. (4) In many autoimmune diseases it takes several weeks, sometimes months, for the full beneficial effect of combined treatment with corticosteroids and azathioprine to be seen. A trial of immunosuppression in schizophrenia would need to continue several (3-6) months in order to be meaningful. The possibility of spontaneous remission would need to be controlled for statistically. (5) In view of the likelihood that 'schizophrenia' encompasses multiple diseases of differing etiologies, it is unlikely that all patients would respond to one type of treatment. Thus, schizophrenia sub-type would need to be carefully recorded at trial entry. Furthermore, in autoimmune diseases that respond to immunosuppression, there is considerable individual variation in responsiveness to particular therapies. Accordingly, to be meaningful and ethical, a trial would have to be appropriately powered to detect an effect in some patients but not others. (6) Patient selection is likely to be important, given the fact that the usual course of schizophrenia has both progressive and relapsing-remitting features. Logically, first episode illness would be most likely to coincide with active autoimmune processes and thus may offer the best chance of effective immunosuppression affecting the disease. On the other hand, it may be ethically easier to justify a novel treatment after conventional treatment has failed, or proven only partially effective. 1 (7) Thus, a trial of immunosuppression could be considered in patients, including those having their first episode, with inadequate response to conventional therapy after a specified time interval (e.g. 1 month) according to one of the following designs: (i) Continued on anti-psychotic drug (APD) treatment and randomized to adjunctive treatment (immunosuppression or placebo); (ii) Withdrawn from initial APD, given alternative APD plus randomized adjunctive treatment (immunosuppression or placebo); (iii) Withdrawn from initial APD and randomized to alternative APD or immunosuppression.
Option (iii) is the most difficult to justify on ethical grounds, followed by (i), then (ii). In terms of statistical power to detect an effect of immunosuppression, the order is (i) > (iii) > (ii). Accordingly, (i) may provide the best trade-off between ethics and power, whereas (ii) would be easier to justify in the present ethical climate. Option (i) has the further advantage of allowing for dose optimization of initial APD and monitoring of delayed responses.
(8) As a result of its documented effects on the immune system, clozapine should probably be avoided. Apart from clozapine, APDs could be whatever the treating physician was accustomed to prescribing, and the nature of the drug (first generation, second generation) used as a grouping variable in the analysis. Other psychotropics (e.g. hypnotics and antiparkinson agents) would need to be carefully monitored and included as covariates in the analysis. (9) Outcome measures would need to include validated, sensitive scales for the various symptom clusters of schizophrenia (positive, negative, disorganized) as these may be differentially affected by treatment. They would also need to include measures of side effects and quality of life. A possible set of outcome measures selected from those used by Jones et al. 1 is: Positive and Negative Syndrome Scale (PANSS); SimpsonAngus EPS rating scale; Barnes Akathisia Rating Scale; Antipsychotic Non-Neurological Side-Effects Rating Scale (especially important for second generation anti-psychotics); Quality of Life Scale (QLS); Participant Satisfaction Scale.
Conclusion
Several decades of research effort have failed to provide clear indications of causative mechanisms in schizophrenia. We review the many sources of evidence pointing to autoimmune processes. Widely accepted immunosuppressive therapy developed and refined for treating many autoimmune diseases should be trialled for efficacy in schizophrenia. This could provide valuable insights into aetiology, as well as providing principles for effective therapy.
